Pharmaceuticals FDA Approves Expanded Use of Almirall’s Crisiri to Treat Actinic Keratosis Last updated: June 12, 2024 2:26 am By bexib 0 Min Read Share SHARE Klisyri is currently available in a 350 mg package size as a topical treatment for actinic keratosis of the face or scalp. You Might Also Like APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins New ways to determine drug value with health equity in mind Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer Share This Article Facebook Twitter Email Print Previous Article How to Dropship on eBay (2024 Guide) Next Article Decision time has come for Ontario farmers struggling with unseeded land – RealAgriculture Leave a comment Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. Stay ConnectedFacebookLikeTwitterFollowYoutubeSubscribeTelegramFollowLatest News What is the cause of the deterioration in profits of Commercial Bank of Cambodia? Fintech Australia invests US$50 million in Singapore’s blended finance initiative FAST-P Fintech GROB’s G350 – Machine Insider Manufacturing Graph: The impact of technology on global fund managers, Q4 2024 Retail & E-commerce